World Pharma News Digest - 02.11.2009

0 views
Skip to first unread message

Ruslan David

unread,
Nov 2, 2009, 3:35:44 AM11/2/09
to worldph...@googlegroups.com
Lilly CEO Lechleiter Calls for Repair of the 'Engine of Biopharma Innovation' 
In a speech to the City Club of San Diego, John C. Lechleiter, Ph.D., chairman and chief executive officer of Eli Lilly and Company (NYSE: LLY), said that the engine of biopharmaceutical innovation is "broken." He offered a vision for biopharmaceutical companies to "reinvent innovation" to make the most of today's wealth of scientific knowledge to benefit patients and address unmet medical needs. 
Read more... 
http://www.worldpharmanews.com/content/view/1004/1/
 
Novartis on track to deliver Influenza A (H1N1) vaccine for the US 
Novartis has shipped over 7.5 million doses of Influenza A(H1N1)[1] vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in pre-filled syringes and multi-dose vials by the end of November. Smaller changes in delivery timelines and volumes can result out of the variability of the underlying biological production process. The deliveries are in line with commitments made to the US Department of Health and Human Services (HHS). 
Read more... 
http://www.worldpharmanews.com/content/view/1003/1/
 
Novel agent for treatment of Parkinson's disease - Lu 02-750 
H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. The placebo-controlled study is expected to enrol around 100 healthy individuals. 
Read more... 
http://www.worldpharmanews.com/content/view/1002/1/
 
Novo Nordisk increased operating profit by 30% in the first nine months of 2009 
Sales increased by 15% in Danish kroner and by 11% in local currencies:
Sales of modern insulins increased by 28% (24% in local currencies).
Sales of NovoSeven® increased by 15% (11% in local currencies).
Sales of Norditropin® increased by 15% (9% in local currencies).
Sales in North America increased by 29% (17% in local currencies).
Sales in International Operations increased by 18% (16% in local currencies).
Read more... 
http://www.worldpharmanews.com/content/view/1001/1/
 
AstraZeneca PLC Third Quarter & Nine Months Results 2009 
Revenue in the third quarter increased by 10 percent at CER, but was up 5 percent on an actual basis as a result of the negative impact of exchange rate movements. Revenue benefited from strong growth of the Toprol-XL franchise in the US as a result of the market withdrawal by two generic competitors and from revenues from US government orders for vaccine for Novel Influenza A (H1N1); adjusting for these factors, global revenue increased by 5 percent. 
Read more... 
http://www.worldpharmanews.com/content/view/1000/1/
 
Abbott Completes Visiogen Acquisition 
Abbott (NYSE: ABT) has completed its acquisition of privately held eye care company Visiogen, expanding the company's vision care business with a next-generation accommodating intraocular lens (IOL) technology to address presbyopia for cataract patients. 
Read more... 
http://www.worldpharmanews.com/content/view/999/1/
 
Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase IIb Study of Cariprazine 
Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia. 
Read more... 
http://www.worldpharmanews.com/content/view/998/1/
 
Pandemrix™ data in an elderly population 
GlaxoSmithKline (GSK) announced that this week, approximately half a million people will have received its pandemic H1N1 vaccine, Pandemrix™, as part of Government initiated vaccination programmes across Europe, which commenced earlier this month. GSK also announced new results from a clinical trial assessing the use of Pandemrix in adults aged 18 to 85 years of age. 
Read more... 
http://www.worldpharmanews.com/content/view/997/1/
 
Boehringer Ingelheim Animal Health closes deal to acquire Animal Health Business from Pfizer 
Boehringer Ingelheim, a global pharmaceutical group of companies, together with its U.S. animal health business Boehringer Ingelheim Vetmedica, Inc., has closed its deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business. 
Read more... 
http://www.worldpharmanews.com/content/view/996/1/
 
Novartis delivers strong new product momentum and operational performance 
Novartis maintained the strong underlying momentum of 2009 as third-quarter net sales grew 7% in local currencies, while reported net sales rose 3% to USD 11.1 billion as four percentage points of growth were lost to adverse currency movements. 
Read more...
http://www.worldpharmanews.com/content/view/995/1/
 
PharmaNews.eu / Latest News
 
 
Novo Nordisk increased operating profit by 30% in the first nine months of 2009
http://www.pharmanews.eu/novo-nordisk/368-novo-nordisk-increased-operating-profit-by-30-in-the-first-nine-months-of-2009
 
 
 
 
 
European Medicines Agency 2009 mid-year report shows it is still on target, despite influenza pandemic activities
http://www.pharmanews.eu/emea/363-european-medicines-agency-2009-mid-year-report-shows-it-is-still-on-target-despite-influenza-pandemic-activities
 
 
Experience of GSK's H1N1 adjuvanted vaccine, Pandemrix™, and preliminary paediatric results
http://www.pharmanews.eu/gsk/361-experience-of-gsks-h1n1-adjuvanted-vaccine-pandemrix-and-preliminary-paediatric-results
 
The risk of venous thromboembolism (VTE) associated with oral hormonal contraceptives
http://www.pharmanews.eu/bayer/360-the-risk-of-venous-thromboembolism-vte-associated-with-oral-hormonal-contraceptives
 
With best regards,
Ruslan David, MD
Administrator/Editor
 
 
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
 
Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
Reply all
Reply to author
Forward
0 new messages